Patients with a postoperatively high proportion of CD203a expressing Th17 cells (CD4+ CCR6+ CCR4+) showed a sixfold increased risk (HR 6.38, 95% Cl 1.51–27.00) with of HCC recurrence and a median recurrence-free survival of 233 days (Fig. 4C), compared to CD203a Th17 cells with low expression (CCR6+ CCR4+). This evidence concerns the gene CCR6 and hepatocellular carcinoma.